Get the Daily Brief
Latest Biotech News
Nucleai and BostonGene expand AI spatial‑biology efforts with academic partners
Two AI‑driven collaborations advanced tissue biomarker discovery: Nucleai partnered with the University of Glasgow to develop multimodal spatial biomarkers for colorectal cancer and risk...
Lilly doubles down on genetic medicine: vision gene‑therapy deal and $1.2B RNAi pact
Eli Lilly expanded its genetic‑medicine footprint with two major moves: a licensing agreement with MeiraGTx for an AAV‑AIPL1 gene therapy that restored vision in pediatric LCA4 patients and a $1.2...
Beacon raises $86M — building a brain‑wave dataset to power neurology R&D
Beacon Biosignals closed an $86 million financing to scale a longitudinal brain‑wave dataset intended to accelerate drug development and diagnostics for neurological diseases. The company will...
FDA taps Pazdur: Veteran oncology chief named CDER director
The FDA on Nov. 11 installed Richard Pazdur — the agency’s longtime oncology director — as head of the Center for Drug Evaluation and Research (CDER). The appointment follows the abrupt departure...
AbbVie exits Calico: 11-year aging partnership wound down, layoffs follow
AbbVie notified staff that it will end its 11-year collaboration with Alphabet’s Calico Labs and is preparing layoffs tied to the wind‑down of joint aging projects. The partnership — which AbbVie...
Nilo launches with $101M: Neuro‑immunology startup aims to rewire inflammation
Nilo Therapeutics launched from New York with $101 million in Series A backing to translate neuro‑immunology discoveries into therapies for autoimmune and inflammatory conditions. The company was...
Lilly licenses MeiraGTx gene therapy: $75M upfront for AAV‑AIPL1 in childhood blindness
Eli Lilly agreed to acquire exclusive worldwide rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front and up to $400 million in...
EnGene/Engene posts pivotal bladder data — shares surge on Phase II results
Two related updates from EnGene/Engene reinforced plans for a biologics license application in high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer. The companies reported additional...
CRISPR’s mixed week: therapy win shadowed by fatal trial event
The CRISPR therapeutics sector reported divergent news this week: positive clinical data for a CRISPR‑based cholesterol treatment contrasted with a fatal adverse event in Intellia’s MAGNITUDE...
Beacon Biosignals raises $86M to assemble brain‑wave dataset for neurology R&D
Beacon Biosignals closed an $86 million financing to build a large, standardized brain‑wave database intended to accelerate neurological drug and diagnostic development. The company plans to...
MGI, South Africa launch 110K genome program: first national African reference
MGI Tech signed an MoU with South African research and government bodies to sequence up to 110,000 genomes and establish the country’s first national genomic reference. The program installs MGI’s...
Lilly doubles down on RNAi: $1.2B deal for Sanegene’s tissue‑selective delivery tech
Eli Lilly agreed to a $1.2 billion partnership with Suzhou Sanegene Bio to access tissue‑selective RNAi delivery platforms for metabolic disease programs, including obesity. The transaction gives...
GLP‑1 sales top $20B in 3Q25 — Mounjaro and Zepbound lead market surge
Third‑quarter sales of GLP‑1 receptor agonists exceeded $20 billion, driven by strong demand for Lilly’s Mounjaro and new entrants such as Zepbound. The data, compiled by BioCentury, underscore...
FDA names Richard Pazdur as CDER director
The FDA appointed longtime oncology regulator Richard Pazdur to lead the Center for Drug Evaluation and Research (CDER). The change comes after George Tidmarsh’s abrupt departure and aims to...
Lilly acquires MeiraGTx gene therapy rights and deepens AI drug discovery ties
Eli Lilly agreed to acquire global rights to MeiraGTx’s AAV-AIPL1 gene therapy for Leber congenital amaurosis 4 and struck an expanded AI drug-discovery collaboration with Insilico Medicine. Lilly...
Pfizer closes $10 billion Metsera deal — Washington ties surfaced
Pfizer won the bidding war for obesity developer Metsera with an amended agreement valuing the company at about $10 billion. Novo Nordisk withdrew from further bidding after a week-long contest....
FDA moves to strip boxed warnings from menopause hormone therapies
The FDA announced actions to remove or narrow long-standing black box warnings from hormone replacement therapies used for menopause. Agency leaders said the earlier warnings overstated...
Neurocrine’s Takeda‑licensed depression candidate fails mid‑stage tests
Neurocrine Biosciences reported that NBI‑1070770, a compound licensed from Takeda for major depressive disorder, did not meet its primary endpoint in a Phase 2 study. The company said the drug was...
Engene posts pivotal Phase II detalimogene data — shares spike
Engene Holdings released additional preliminary pivotal‑cohort data from its Phase II Legend trial of detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer...
Metagenomi trims workforce while hemophilia program posts strong NHP data
Gene‑editing firm Metagenomi announced a restructuring that cut roughly 25% of its staff, including the CEO, to focus resources on its preclinical hemophilia A program. The move accompanies new...